Proactive Immune Tolerance Induction in Chemotherapy for Gynecologic Cancer

Launched by SEOUL NATIONAL UNIVERSITY HOSPITAL · May 14, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new approach to help women with ovarian, endometrial, or cervical cancer who are receiving chemotherapy. The researchers want to find out if a treatment called immune tolerance induction can help prevent allergic reactions to the chemotherapy drugs paclitaxel and carboplatin during the first three cycles of treatment. If successful, this could make the treatment process easier and safer for patients.

To be eligible for this trial, participants must be women aged 19 or older who are starting chemotherapy with paclitaxel and carboplatin for the first time. Those who join will either receive the new immune tolerance treatment or standard chemotherapy during the first three cycles. After that, all participants will continue with the regular chemotherapy for the remaining cycles. It's important to note that the trial is not yet recruiting participants, but it aims to help improve the treatment experience for women facing these cancers.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Patients receiving paclitaxel and carboplatin chemotherapy for gynecologic malignancies.
• • Patients with no prior history of hypersensitivity reactions to paclitaxel or carboplatin.
• • Patients who are able to read and voluntarily provide written informed consent.
• • Aged 19 years or older.
• Exclusion Criteria:
• • Patients who do not wish to participate in this study voluntarily.
• • Patients who, in the opinion of the investigator, are unsuitable for participation in this clinical trial.